Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
144.63M | 210.26M | 214.00M | 200.50M | 222.19M | Gross Profit |
76.55M | 58.18M | 46.02M | 43.39M | 65.93M | EBIT |
-8.18M | 8.49M | 875.00K | 831.00K | 26.46M | EBITDA |
-4.92M | 8.51M | 7.44M | 2.57M | 23.51M | Net Income Common Stockholders |
-15.99M | -5.06M | 333.00K | -5.37M | 6.06M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
24.77M | 7.03M | 13.14M | 7.35M | 7.15M | Total Assets |
146.90M | 190.06M | 215.76M | 199.59M | 190.82M | Total Debt |
19.85M | 25.45M | 29.38M | 20.93M | 24.67M | Net Debt |
-4.92M | 18.42M | 16.24M | 13.57M | 17.52M | Total Liabilities |
57.26M | 80.61M | 94.95M | 84.96M | 100.59M | Stockholders Equity |
89.64M | 109.45M | 120.81M | 114.62M | 90.23M |
Cash Flow | Free Cash Flow | |||
9.64M | 4.70M | 16.32M | 168.00K | 17.52M | Operating Cash Flow |
12.34M | 6.55M | 18.57M | 2.69M | 19.33M | Investing Cash Flow |
16.29M | -1.85M | -2.25M | -31.80M | -8.14M | Financing Cash Flow |
-10.90M | -10.91M | -10.59M | 29.42M | -14.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $28.84B | 25.99 | 30.87% | 3.98% | 6.00% | 4.02% | |
73 Outperform | €242.50M | 39.19 | 3.33% | 1.54% | 3.37% | -25.24% | |
60 Neutral | $6.78B | 11.63 | 3.24% | 4.20% | 2.36% | -21.91% | |
49 Neutral | €38.15M | ― | -14.68% | 8.87% | -44.48% | -419.84% | |
46 Neutral | $4.78B | 23.42 | -1.04% | ― | -65.07% | -102.37% |
McPherson’s Limited has announced a strategic shift in its operating model by transitioning from direct-to-store orders to utilizing a third-party logistics provider and pharmacy wholesalers. This change is marked by a new three-year agreement with Symbion Pty Ltd, starting June 2025, which will handle an estimated $10-$15 million in annual revenue previously managed under the direct-to-store model. This move is expected to streamline operations and potentially enhance McPherson’s market positioning by leveraging Symbion’s distribution capabilities.
McPherson’s Limited has announced a strategic shift in its operating model by exiting its warehousing and direct-to-store orders, opting instead to partner with third-party logistics and pharmacy wholesalers. This transition includes a new three-year agreement with Sigma Company Limited, which will handle orders previously managed directly by McPherson’s, impacting annual revenue of approximately $50 – $55 million. This move is expected to streamline operations and potentially enhance the company’s market positioning by leveraging Sigma’s distribution capabilities.
McPherson’s Limited announced that Ari Mervis will temporarily step down as Chair of the Board effective March 10, 2025, due to increased external commitments. Alison Cook, a current Non-Executive Director, will serve as interim Chair, ensuring continuity in leadership. This change reflects the company’s adaptive management strategy and may impact its governance dynamics, but the continuity of Mervis as a Non-Executive Director ensures ongoing stability.
McPherson’s Limited has announced its financial results for the half-year ending December 31, 2024, which will be presented in a webcast hosted by the CEO and CFO. This presentation is an opportunity for shareholders to gain insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
McPherson’s Limited announced a challenging first half of the 2025 financial year, with revenue from continuing operations declining by 7.6% to $70.7 million. The company reported a statutory net loss after tax of $0.9 million, compared to a net profit of $1.6 million in the previous period. Despite these setbacks, McPherson’s is making progress on its transformation strategy, supported by a strong balance sheet. The company is implementing a new operating model that will transition to third-party warehousing and logistics, aiming to streamline operations and focus on core brands. This strategic shift is expected to address residual fixed costs and create a scalable cost base for future growth.
McPherson’s Limited reported a decline in sales revenue by 7.6% to $70.7 million for the half-year ended December 31, 2024, compared to the previous period. The company also experienced a loss from continuing operations both before and after tax, indicating financial challenges. The absence of an interim dividend further highlights the company’s current financial strain, impacting shareholder returns.
McPherson’s Limited announced it will release its first half year results for the period ending 31 December 2024 on 26 February 2025. The company is hosting an investor briefing via webcast and conference call to discuss these financial and operational results. This announcement is significant as it provides stakeholders with insights into the company’s performance and strategic direction, potentially impacting its market positioning and investor confidence.
McPherson’s Limited has announced a significant shift in its operating model, transitioning from a direct-to-store approach to utilizing third-party logistics and pharmacy wholesalers. This new model is expected to streamline operations, enhance brand growth, and improve distribution efficiency, leading to an anticipated annual EBIT increase of $4.0 to $5.0 million from FY26. However, the transition will impact approximately 65 warehouse roles and incur costs between $9.0 million to $11.0 million in FY25, including redundancy and implementation expenses.
McPherson’s Limited announced that its CEO, Brett Charlton, has been charged with an unrelated legal matter from his previous employment in 2018. Despite this, Mr. Charlton remains committed to his role, and the board is monitoring the situation closely to assess any potential implications for the company.